Recently Published Issues

Happy Authors

Recently Published Articles

  • 2020, May

    case report

    Profile of Blood Glucose in Diabetic Patient Suffered from Diabetic Foot Osteomyelitis with Effective Low Carbohydrate DietOpen Access
    PDF452.06 KB 452.06 KB
    Full-Text (HTML)
    Abstract [+]

    The case was 52-year-old female with type 2 diabetes mellitus (T2DM) for 10-years. She complained of the decreased sensation of right lower foot, and revealed diabetic foot infection (DFI) and/or diabetic foot osteomyelitis (DFO) at right 1st proximal phalanx. Various data included body mass index (BMI) 33.3 kg/m2, HbA1c 11.4%, blood glucose 430 mg/dL, WBC 12100 /μL, C-reactive Protein (CRP) 13.5 mg/dL. On admission (day 1), she was started by 4 times of injection (Aspart and Glargin) with glucose profile 200-500 mg/dL. Surgical amputation of the right toe was performed between 1st metatarsal and proximal phalanx (day 17). Then, blood glucose profile decreased moderately. After discharge of the hospital, super-Low Carbohydrate Diet (LCD) was started without Aspart (day 37). Consequently, glucose profile was normalized with HbA1c 6.3% on (day 77). Consequently, LCD was evaluated to be effective for glucose variability in this case and some related discussion was described.

    Keywords

    Diabetic foot infection (DFI); Diabetic foot osteomyelitis (DFO); Low Carbohydrate Diet (LCD); Japanese LCD promotion association (JLCDPA); International Working Group on the Diabetic Foot (IWGDF).

    Abbreviations

    DFI: Diabetic foot infection; DFO: Diabetic foot osteomyelitis; LCD: Low carbohydrate diet; JLCDPA: Japanese LCD promotion association; IWGDF: International Working Group on the Diabetic Foot.

  • 2020, May

    editorial

    Recent Tendency of Therapeutic Medical Agents for Diabetic Peripheral Neuropathic PainOpen Access
    PDF327.50 KB 327.50 KB
    Full-Text (HTML)
    Abstract [+]

    Recently, elder patients tend to have neuropathic pain such as lower back and joints pain, stiff shoulders, besides diabetic neuropathy. Typical peripheral neuropathic pain includes diabetic peripheral neuropathic pain (DPNP), postherpetic neuralgia (PHN) and chronic pain due to herniated disc. Three analgesic agents are described. Pregabalin (Lyrica®) has been prevalent worldwide. However, it has been provided for several diseases for off-label administration, which has been one of the clinical problems.Mirogabalin (Tarlige®) has revealed efficacy for DPNP in a dose-dependent manner. Duloxetine hydrochloride (Cymbalta®) has efficacy for pain and also depression as serotonin and noradrenaline reuptake inhibitor (SNRI).

    Keywords

    Neuropathic pain; Pregabalin; Mirogabalin; Duloxetine hydrochloride; Diabetic peripheral neuropathic pain (DPNP).

    Abbreviations

    DPNP: Diabetic peripheral neuropathic pain; PHN: Postherpetic neuralgia; CRPS: Complex regional pain syndrome; FDA: Food and Drug Administration.

About the Journal

Diabetes Research- Open Journal (DROJ) aims to serve the scientific community and provide information focusing on the various causes, diagnosis,  treatments, prevention, education, management and research related to diabetes.

Diabetes is a systemic disease which causes higher than normal blood sugar levels and results in a number of symptoms and complications of varying severity. While the symptoms and complications are similar, treatment will vary depending on the type of diabetes that is diagnosed. The disease is classified into various types, based upon the underlying pathophysiology.

Thus, a diagnosis of diabetes is usually classified as either Type I or diabetes Mellitus (DM); or Type II or Diabetes Insipidus (DI). Type I diabetes is caused by the failure of the beta cells in the pancreas to produce sufficient insulin; while Type II diabetes is due to cells’ inability to recognize the insulin that is being produced; a phenomenon known as ‘insulin resistance’. Gestational diabetes is a third, less common type of diabetes-specific to pregnant women.

DROJ strives to provide widespread and open access to detailed, up-to-date, and reliable information of the highest quality on all matters related to diabetes – including effective disease prevention measures, management strategies, and pharmacological treatments; innovative research findings and applications; and associated disorders – through Openventio Publisher’s Open Journal approach.

Aims and Scope

Diabetes Research – Open Journal (DROJ) is dedicated to the open dissemination of scientific information and robust discussion in all areas relating to diabetes, amongst professionals with diverse backgrounds and varying perspectives, such as researchers, educators, public health professionals, and clinicians. The DROJ audience includes physicians, surgeons, nurses, and other clinicians from a wide array of specialties, researchers, educators, and students.

DROJ covers a wide array of subjects as given below

  • Latest research advances in diabetes
  • Public health policies in diabetes
  • Diagnostic criteria and treatment protocols
  • Diabetic foot care
  • Metabolic syndrome
  • Diabetes drugs
  • Diabetic diet
  • Obesity, hypertension in diabetes
  • Endocrinology
  • Retinopathy, nephropathy and peripheral artery disease (PAD)
  • SGLT2 inhibitors
  • Low Carbohydrate Diet (LCD)

DROJ  welcomes all types of articles such as: original clinical research and case-reports, literature reviews and mini-reviews, opinion pieces such as editorials, commentary, and book reviews, technical reports, conference materials, illustrations, etc.

As we strive to improve the quality of our journal, any comments or suggested corrections from readers are welcome. Please send us your thoughts using the Contact Us link.